VeraDermics (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- December 11, 2024
- Vertical
- Biopharmaceutical
- Funding URL
- View Funding Page
- Funding Amount:
- $75,000,000
Company Info
- Traction
- The first patient has been dosed in the pivotal Phase 2/3 trial evaluating VDPHL01 in AGA/PHL, which will enroll approximately 480 patients across 44 sites in the United States.
- Company Description
- VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions such as warts.
- Market
- Aesthetics and dermatology
- Location
- New Haven, Connecticut, United States
- Coinvestors
- Longitude Capital, Surveyor Capital, Osage University Partners, PhiFund, JW Childs Associates, Connecticut Innovations, Vlad Coric, MD